Independent pharmacies are usually financed with an SBA 7(a) loan at roughly 10–20% down — the program fits because the value is mostly the prescription file, inventory, and goodwill rather than hard collateral. Lenders who know pharmacy normalize cash flow for PBM reimbursement and DIR fees, value the script base and payer mix, and often pair the acquisition loan with a line of credit to cover insurance receivables and drug inventory. The same structure works for a de novo (startup) pharmacy or a partner buy-in.
Buying or starting an independent pharmacy is a financing problem built around intangibles: a prescription file, a payer mix, and a margin structure that's squeezed by the PBMs. The SBA funds these deals regularly, but the underwriting looks different from a typical retail acquisition. Here's how it works for an acquisition, a startup, or a partner buy-in.
The Prescription File Is the Asset
The core value of an independent pharmacy is its prescription file — the script count, refill base, and the payer mix behind it. Lenders and buyers underwrite on prescription volume, gross profit per script, and how durable the patient base is. Watch for concentration: a pharmacy leaning on one nursing-home contract or a single 340B relationship carries more risk than a broad retail base. Because the deal is mostly intangible value plus inventory, this is squarely SBA 7(a) territory — a conventional bank rarely lends against a script file.
PBM & DIR Margin Pressure
Pharmacy margins are pressured by PBM reimbursement and DIR (direct and indirect remuneration) fees that can pull back margin after a script is already filled. A lender who finances pharmacies builds this into the cash-flow analysis — they want gross margin per script and payer mix, not just revenue. A buyer who can articulate a plan to offset that pressure (front-end retail sales, immunizations and clinical services, adherence/med-sync programs, compounding) presents a materially stronger file.
Financing Options
| Option | Best for | Typical down payment |
|---|---|---|
| SBA 7(a) | Acquisition, de novo startup, or partner buy-in (script file + inventory + goodwill, up to $5M) | 10–20% |
| SBA 504 | When you're also buying the building | ~10–15% |
| Line of credit / AR facility | Insurance receivables & drug inventory working capital | n/a (revolving) |
| Equipment loan | Robotics/automation, compounding equipment, POS/IT | 0–15% |
For acquisitions and partner buy-ins, see using an SBA loan to buy a business.
Insurance AR & Inventory
- Insurance receivables: a large share of revenue sits in third-party AR between filling a script and getting paid. A line of credit or AR facility bridges that gap so payroll and inventory buying never stall.
- Drug inventory is sizable and turns; it's valued at acquisition and replenished through working capital.
- Compliance: DEA registration, state board licensure, and controlled-substance recordkeeping are confirmed as part of closing.
What Lenders Check
- Script volume & gross margin per script, plus payer-mix concentration.
- Normalized cash flow net of DIR/PBM clawbacks; DSCR ~1.20x+.
- Buyer credentials — typically a licensed pharmacist or strong pharmacy management on the team.
- Clean licensure/DEA and a realistic transition plan to retain patients.
- Growth levers — front-end, clinical services, adherence programs.
See what lenders look for in an SBA loan.
Next Step
Whether you're buying an established independent, opening a de novo store, or buying out a partner, the right structure pairs an SBA 7(a) acquisition loan with working capital for AR and inventory. Get matched with pharmacy lenders who understand script-file valuation and reimbursement pressure.